PRAME
A protein normally confined to testis that most melanomas and many other cancers switch on; T-cell receptor drugs can recognise fragments of it. This dossier gathers the 1 product (0 approved), 1 trial, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Represses retinoic acid receptor signalling; drives proliferation and blocks differentiation; presented on HLA class I as peptides such as PRAME 425-433 on A*02:01.
- Cutaneous melanoma (~90%)
- Uveal melanoma (subset, associated with metastasis)
- Ovarian, endometrial, NSCLC, breast (subsets)
- Synovial sarcoma
Elsewhere: identifiers and databases
Built from HGNC, Ensembl, UniProt and ChEMBL idsHow common it is, by cancer
Full matrix →Products by modality and phase
Browse products →| Modality | Phase 3 |
|---|---|
| T-cell engager 1 |
Trials
Evidence ranking →| Trial | Phase | Status | Setting | Result | Products |
|---|---|---|---|---|---|
| PRISM-MEL-301 NCT06112314 | 3 | Recruiting | Untreated HLA-A*02:01-positive advanced cutaneous melanoma: brenetafusp + nivolumab vs nivolumab-based regimens |
Resistance routes that involve this target
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways where it is a node
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics and assays
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Ideas and companies
Key papers and the live literature
Preprints →Query for this target: (TITLE:"PRAME" OR ABSTRACT:"PRAME") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PRAME, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/prame.json. Licence CC BY 4.0.